Compare UXIN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | BBNX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | 423 |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 493.1M |
| IPO Year | 2018 | N/A |
| Metric | UXIN | BBNX |
|---|---|---|
| Price | $1.91 | $13.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 112.3K | ★ 872.0K |
| Earning Date | 04-10-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $245.77 | $34.90 |
| Revenue Next Year | $44.72 | $34.63 |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $8.80 |
| 52 Week High | $5.32 | $32.71 |
| Indicator | UXIN | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.58 | 60.96 |
| Support Level | N/A | $9.34 |
| Resistance Level | $3.18 | $15.53 |
| Average True Range (ATR) | 0.15 | 0.98 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 22.63 | 66.25 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.